Related Experiment Video
Updated: Oct 21, 2025
In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines
Published on: April 18, 2025
lncRNA TPT1‑AS1 knockdown inhibits liver cancer cell proliferation, migration and invasion
Hao Li1, Jing Jin2, Jianchun Xian1
1Department of Infectious Diseases, Taizhou People's Hospital, Taizhou, Jiangsu 225300, P.R. China.
Abstract:
Long non‑coding RNA (lncRNA) tumor protein translationally controlled 1 antisense RNA 1 (TPT1‑AS1) serves as an oncogene in several tumors, including ovarian and cervical cancer. However, the functional role of TPT1‑AS1 in liver cancer (LC) is not completely understood. The present study aimed to explore the role of TPT1‑AS1 in LC. In this study, the reverse transcription‑quantitative PCR results demonstrated that TPT1‑AS1 expression was significantly upregulated in LC tissues and cell lines compared with adjacent paracancerous tissues and THLE‑3 cells, respectively. Elevated TPT1‑AS1 expression was significantly associated with TNM stage lymph node metastasis and poor prognosis in patients with LC, as determined via χ2 and Kaplan‑Meier survival analyses. By constructing TPT1‑AS1 knockdown LC cell lines (HepG2 and SNU‑182), loss‑of‑function experiments, including Cell Counting Kit‑8, colony formation, flow cytometry, wound healing and Transwell assays, were performed to explore the function role of TPT1‑AS1 in LC in vitro. The results demonstrated that TPT1‑AS1 knockdown inhibited LC cell proliferation, G1/S transition, migration and invasion compared with the small interfering RNA (si)‑negative control (NC) group. Mechanistically, TPT1‑AS1 knockdown markedly decreased CDK4, N‑cadherin and Vimentin expression levels, but notably increased p21 and E‑cadherin expression levels compared with the si‑NC group. Therefore, the results of the present study suggested that TPT1‑AS1 might serve as a promising therapeutic target for LC treatment.
Insights
Long non-coding RNA TPT1-AS1 is upregulated in liver cancer (LC) and promotes cell proliferation and metastasis. Inhibiting TPT1-AS1 shows potential for LC treatment by reducing tumor growth and spread.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Long non-coding RNA (lncRNA) tumor protein translationally controlled 1 antisense RNA 1 (TPT1-AS1) is implicated as an oncogene in various cancers.
- The specific role of TPT1-AS1 in liver cancer (LC) remains largely uncharacterized.
Purpose of the Study:
- To investigate the functional role and clinical significance of TPT1-AS1 in liver cancer.
- To explore TPT1-AS1 as a potential therapeutic target for LC.
Main Methods:
- Quantitative PCR to assess TPT1-AS1 expression in LC tissues and cell lines.
- Survival analysis (Kaplan-Meier) and correlation analysis (chi-squared) to evaluate clinical significance.
- In vitro loss-of-function studies using TPT1-AS1 knockdown in LC cell lines (HepG2, SNU-182) with assays for proliferation, cell cycle, migration, and invasion.
- Western blot analysis to determine the impact on key protein expression levels (CDK4, N-cadherin, Vimentin, p21, E-cadherin).
Main Results:
- TPT1-AS1 expression is significantly upregulated in LC tissues and cell lines.
- Elevated TPT1-AS1 levels correlate with advanced TNM stage, lymph node metastasis, and poorer prognosis in LC patients.
- TPT1-AS1 knockdown suppressed LC cell proliferation, G1/S transition, migration, and invasion.
- Knockdown of TPT1-AS1 led to decreased expression of CDK4, N-cadherin, and Vimentin, and increased expression of p21 and E-cadherin.
Conclusions:
- TPT1-AS1 acts as an oncogene in liver cancer, promoting tumor progression.
- TPT1-AS1 is associated with adverse clinical outcomes in liver cancer patients.
- Targeting TPT1-AS1 represents a promising therapeutic strategy for liver cancer treatment.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
02:15Experimental RNAi